Science
CME credits: 0.25 Valid until: 18-09-2021 Claim your CME credit at https://reachmd.com/programs/cme/the-role-of-targeted-therapy-in-severe-asthma-with-type-2-inflammation/11677/ There's been an emergence of novel therapies for the treatment of severe asthma, including biologics targeting inflammatory pathways. These therapeutic options have ushered in a new era of personalized asthma management, which is why clinicians must be able to identify which patients are most likely to respond to newer biologic agents and need to be knowledgeable of the biologic and physiologic markers that form the basis for selecting a treatment.